​

Voyager Therapeutics (VYGR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VYGR Stock Forecast

Voyager Therapeutics (VYGR) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $18.00, with a high of $18.00 and a low of $18.00. This represents a 218.02% increase from the last price of $5.66.

$5 $8 $11 $14 $17 $20 High: $18 Avg: $18 Low: $18 Last Closed Price: $5.66

VYGR Stock Rating

Voyager Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

VYGR Price Target Upside V Benchmarks

TypeNameUpside
StockVoyager Therapeutics218.02%
SectorHealthcare Stocks 25.00%
IndustryBiotech Stocks 63.52%

Price Target Trends

1M3M12M
# Anlaysts-13
Avg Price Target-$18.00$14.67
Last Closing Price$5.66$5.66$5.66
Upside/Downside-218.02%159.19%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25110---11
Jan, 25110---11
Dec, 2419---10
Nov, 24581--14
Oct, 24581--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 13, 2024Jay OlsonOppenheimer$18.00$6.92160.12%218.02%
Sep 25, 2024Jack AllenRobert W. Baird$18.00$6.04198.01%218.02%
May 14, 2024Laura ChicoWedbush$8.00$8.48-5.66%41.34%
Jan 02, 2024Jim BirchenoughWells Fargo$14.00$9.0055.56%147.35%
May 10, 2023Joon LeeTruist Financial$18.00$9.8882.19%218.02%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2024CitigroupBuyinitialise
Nov 13, 2024OppenheimerOutperformOutperformhold
Oct 16, 2024WedbushBuyBuyhold
Jul 31, 2024WedbushBuyBuyhold
May 14, 2024WedbushNeutralNeutralhold
May 10, 2023UBSBuyinitialise

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.99$-1.75$-1.21$3.08-----
Avg Forecast$0.85$-2.34$-1.16$1.44$-0.92$-1.60$-1.34$-1.31$-0.68
High Forecast$0.35$-3.73$-1.96$1.35$-1.07$-3.11$-2.20$-2.05$-1.42
Low Forecast$1.35$-0.96$-0.17$1.50$-0.67$-0.64$-0.55$-0.77$0.16
Surprise %16.47%-25.21%4.31%113.89%-----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$171.13M$37.41M$40.91M$250.01M-----
Avg Forecast$180.41M$13.62M$46.16M$179.77M$90.30M$68.24M$79.33M$78.19M$110.38M
High Forecast$98.54M$7.44M$15.86M$179.40M$85.71M$3.07M$76.87M$78.19M$5.62M
Low Forecast$262.75M$19.84M$70.73M$180.41M$94.99M$110.54M$81.79M$78.19M$202.31M
Surprise %-5.14%174.70%-11.39%39.07%-----

Net Income Forecast

$-500M $-100M $300M $700M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$36.74M$-66.03M$-46.41M$132.33M-----
Avg Forecast$1.01B$-104.45M$-109.02M$132.33M$-38.68M$-103.67M$-61.48M$-62.84M$-30.31M
High Forecast$786.50M$-166.43M$-130.82M$105.86M$-47.50M$-138.58M$-98.26M$-91.36M$-63.12M
Low Forecast$1.24B$-42.83M$-87.21M$158.80M$-29.86M$-28.35M$-24.69M$-34.32M$7.09M
Surprise %-96.38%-36.78%-57.43%------

VYGR Forecast FAQ

Is Voyager Therapeutics stock a buy?

Voyager Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Voyager Therapeutics is a favorable investment for most analysts.

What is Voyager Therapeutics's price target?

Voyager Therapeutics's price target, set by 4 Wall Street analysts, averages $18 over the next 12 months. The price target range spans from $18 at the low end to $18 at the high end, suggesting a potential 218.02% change from the previous closing price of $5.66.

How does Voyager Therapeutics stock forecast compare to its benchmarks?

Voyager Therapeutics's stock forecast shows a 218.02% upside, outperforming the average forecast for the healthcare stocks sector (25.00%) and outperforming the biotech stocks industry (63.52%).

What is the breakdown of analyst ratings for Voyager Therapeutics over the past three months?

  • February 2025: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Voyager Therapeutics’s EPS forecast?

Voyager Therapeutics's average annual EPS forecast for its fiscal year ending in December is $-0.92 for 2024, a -129.87% decrease from the reported $3.08 in 2023. The prediction for 2025 is $-1.6, $-1.34 for 2026, $-1.31 for 2027, and $-0.68 for 2028.

What is Voyager Therapeutics’s revenue forecast?

Voyager Therapeutics's average annual revenue forecast for its fiscal year ending in December is $90.3M for 2024, a -63.88% decrease from the reported $250.01M in 2023. The forecast for 2025 is $68.24M, $79.33M for 2026, $78.19M for 2027, and $110.38M for 2028.

What is Voyager Therapeutics’s net income forecast?

For its fiscal year ending in December, Voyager Therapeutics's average annual net income forecast is $-38.681M for 2024, reflecting a -129.23% decrease from the reported $132.33M in 2023. The projection for 2025 is $-104M, $-61.478M for 2026, $-62.84M for 2027, and $-30.307M for 2028.